Nuclear factor-jB (NF-jB) is a transcription factor that plays an important role in the immune system and cell death. Many viral proteins modulate NF-jB to escape host immune surveillance, promote cell survival, and enhance viral replication. In the present study, we show that NF-jB activity is downmodulated by viral interferon regulatory factor 3 (vIRF3), which is encoded by Kaposi's sarcoma-associated herpesvirus open-reading frame K10.5. vIRF3 repressed NF-jB-dependent transcription in a dose-dependent manner and inhibited the activation of NF-jB induced by tumor necrosis factor (TNF)-a. In vivo studies showed vIRF3 inhibited IjB kinase b (IKKb) activity, but not IKKa activity, resulting in reduced IjB phosphorylation. Immunofluorescence assays showed that vIRF3 interfered with nuclear translocation of NF-jB. In addition, consistent with the inhibition of NF-jB activity, vIRF3 sensitized cells to TNF-a-induced apoptosis. While vIRF3 interacts with IKKb in vitro and in 293T cells, we were unable to demonstrate vIRF3-IKKb interaction in BCBL-1 cells. Our results indicate that vIRF3 can regulate the host immune system and apoptosis via inhibition of NF-jB activity.
Introduction
Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8, is a recently identified human DNA tumor virus strongly associated with the development of Kaposi's sarcoma, body cavity-based primary effusion lymphoma (PEL), and multicentric Castleman's disease (Chang et al., 1994; Cesarman et al., 1995; Soulier et al., 1995) . Analysis of the KSHV genomic sequence revealed open-reading frames (ORFs) that encode a number of accessory proteins and an unusual degree of genetic piracy compared to other herpesvirus groups (Russo et al., 1996; Ganem, 1997; Moore and Chang, 1998) . The KSHV genome contains at least three ORFs encoding proteins with homology to interferon (IFN) regulatory factors (IRFs), including ORF K9-encoded viral (v) IRF1, ORF K11.1-encoded vIRF2, and ORF K10.5-encoded viral interferon regulatory factor 3 (vIRF3)/latency-associated nuclear antigen2 (LANA2). Several groups have demonstrated that vIRF1 functions as a repressor of cellular IFNinduced signal transduction (Gao et al., 1997; Li et al., 1998; Zimring et al., 1998) . The overexpression of vIRF1 in NIH 3T3 cells induced cellular transformation and malignant fibrosarcoma in nude mice, suggesting vIRF1 is a potent oncoprotein (Gao et al., 1997; Li et al., 1998) . vIRF1 associates with cellular tumor suppressor p53, resulting in the inhibition of p53-dependent transcription and apoptosis (Nakamura et al., 2001; Seo et al., 2002) . Furthermore, interaction of vIRF1 with p300/CREB-binding protein (CBP) inhibits CBP transactivation and p300 histone acetyltransferase activity (Burysek et al., 1999a; Li et al., 2000; Seo et al., 2000) . Recently, we and another group demonstrated that vIRF1 also associates with GRIM19, leading to the inhibition of IFN/retinoic acid-induced cell death (Seo et al., 2001; Hu et al., 2002) . vIRF2 shows significant homology with vIRF1 and downmodulates both virusstimulated IFN signal transduction and RelA/p65-stimulated transcriptional activation of the human immunodeficiency virus long terminal repeat terminal promoter (HIV-LTR) (Burysek et al., 1999b; Burysek and Pitha, 2001; Barnes et al., 2002) . In addition, vIRF2 inhibits autophosphorylation of double-strand RNAactivated protein and phosphorylation of its substrates, such as histone 2A and eukaryotic translation initiation factor 2, with the result that vIRF2 antagonizes IFNinduced blocking of viral protein synthesis (Burysek and Pitha, 2001; Barnes et al., 2002) .
vIRF3/LANA2 has partial homology to members of the cellular IRF and vIRF family. Comparison of vIRF3/LANA2 with cellular and viral IRFs amino-acid sequences shows that vIRF3 has significant homology to IRF4 in the carboxy-terminal domain and to vIRF2 in the amino-terminal domain (Lubyova and Pitha, 2000; Rivas et al., 2001) . The vIRF3/LANA2 protein comprises 567 amino acids with an apparent molecular mass of 73 kDa, and constitutively expressed in PEL cells (Rivas et al., 2001; Lubyova et al., 2004) . Although in vitro studies indicate that vIRF3/LANA2 interacts with p53 and inhibits p53-induced apoptosis, in vivo interactions between vIRF3/LANA2 and p53 have not yet been demonstrated. vIRF3/LANA2 is expressed in the majority of KSHV-positive cells from PEL and Castleman's disease tumors, whereas it is not detected in Kaposi's sarcoma spindle cells (Rivas et al., 2001) . For the first time, it was suggested that vIRF3/LANA2 is a nuclear protein functioning as dominant-negative mutants of cellular IRFs (Lubyova and Pitha, 2000; Rivas et al., 2001; Barnes et al., 2002) ; however, recent report suggested that vIRF3 can stimulate the transcriptional activity of cellular IRF3 and IRF7, and it is present both in the nucleus and cytoplasm (Lubyova et al., 2004) .
Nuclear factor-kB (NF-kB) is a transcription factor that plays a critical role in immune responses, inflammation, cytokine-inducible gene expression, and cellular apoptosis (Thanos and Maniatis, 1995; Verma et al., 1995; Baeuerle and Baltimore, 1996; Ghosh and Karin, 2002) . NF-kB represents a complex that is composed of homo-and heterodimers from members of the Rel family (Baeuerle and Baltimore, 1996) . The primary form of NF-kB is a heterodimer of p50 and p65/RelA, and in nonstimulated cells it is normally found in the cytoplasm in an inactive form due to association with the inhibitory protein IkB (Simeonidis et al., 1999) . The subcellular location of NF-kB is regulated by IkB, which masks the NF-kB nuclear localization signal. A variety of cell agonists, such as tumor necrosis factor-a (TNF-a) and interleukin-1, trigger IkB phosphorylation at serines 32 and 36, leading to ubiquitination and degradation of IkB, allowing NF-kB to translocate to the nucleus and ultimately activate transcription of specific genes (Karin and Ben-Neriah, 2000) . Phosphorylation of IkB is meditated by the IkB kinase (IKK) complex that is composed of three subunits: IKKa, IKKb, and IKKg (Karin and Ben-Neriah, 2000; Ghosh and Karin, 2002) . IKKa and IKKb are the catalytic subunits, while IKKg is the regulatory subunit (Zandi et al., 1997; Rothwarf et al., 1998; Rothwarf and Karin, 1999) .
In the present study, we show that KSHV vIRF3/ LANA2 protein downmodulates NF-kB-dependent transcription and selectively inhibits IKKb kinase activity. In addition, we found that vIRF3/LANA2 enhances TNF-a-induced apoptosis. Theses findings reveal KSHV vIRF3/LANA2 inhibits NF-kB activity.
Results

KSHV vIRF3 suppresses TNF-a-induced transcription of NF-kB in 293T cells
To investigate the effect of vIRF3 on NF-kB activity, we performed reporter assays using an NF-kB-dependent promoter. The 293T cells were transiently cotransfected with a reporter plasmid that contained synthetic NF-kBbinding elements fused to the luciferase gene (3 Â NFkB-Luc) and a vIRF3 expression plasmid (pcDNAvIRF3) . At 24 h after transfection, cells were treated with TNF-a for 8 h to stimulate NF-kB activity, after which cells were harvested and assayed for luciferase activity as a measure of NF-kB-dependent gene expression. We found that vIRF3 dose dependently inhibited TNF-a-induced luciferase activity ( Figure 1a ). We performed further transient cotransfection assays in 293T cells using a plasmid reporter containing the promoter of endothelial leukocyte adhesion molecule (pELAM-Luc) to test whether vIRF3 inhibits NF-kBdependent transcription driven by an authentic promoter. We found that TNF-a increased luciferase activity, and this response was dose dependently inhibited by cotransfection of the vIRF3 expression plasmid (Figure 1b) . We also examined transcription driven by an authentic NF-kB-dependent viral promoter by using a human immunodeficiency virus long terminal repeat luciferase reporter (pHIV-LTR-Luc). Consistent with the above data, vIRF3 expression inhibited TNF-ainduced activation of this NF-kB-dependent viral promoter (Figure 1c ). To test whether the effect of vIRF3 on the transcriptional activity of NF-kB is specific, we determined the effect of vIRF3 on Gal4-VP16-driven transcription. Unlike other NF-kB-dependent transcription, vIRF3 did not affect transcription driven by Gal4-VP16 (Figure 1d ). Collectively, these results suggest that vIRF3 specifically downmodulates TNF-a-induced NF-kB activity.
vIRF3 interferes with NF-kB activation
To determine whether vIRF3 inhibits NF-kB-dependent transcription through the suppression of NF-kB, we performed electrophoretic mobility shift assay using an NF-kB-specific probe. The 293T cells were transfected with vIRF3 expression plasmid or IkB-a constitutive repressor mutant expression plasmid, then incubated with TNF-a for 20 min, and nuclear extracts were prepared for electrophoretic mobility shift assay. As expected, nuclear extracts from TNF-a-stimulated cells contained markedly higher NF-kB DNA-binding activity compared to extracts from unstimulated cells (Figure 2, lanes 1 and 2) . Coexpression of vIRF3 dose dependently inhibited this TNF-a-stimulated NF-kB DNA binding (Figure 2 , lanes 3-5). These data suggest that vIRF3 suppresses NF-kB activation. As expected, expression of IkB-a (SS32/36AA) strongly inhibited TNF-a-stimulated NF-kB DNA binding (Figure 2 , lane 6). To confirm that the DNA-protein complexes contained NF-kB, we performed competition-binding assays using competitor DNA. When using extracts from TNF-a-stimulated cells, preincubation with excess (50-fold) unlabeled wild-type kB oligonucleotide diminished the amount of DNA-protein complex, whereas mutated kB oligonucleotide did not affect complex formation (Figure 2, lanes 7-10) . Collectively, these data indicate that the assay measured NF-kB-containing DNA-protein complexes and that vIRF3 inhibits NFkB activation.
vIRF3 downregulates TNF-a-induced IkB-a phosphorylation
Cytokines such as TNF-a induce IkB phosphorylation, causing it to dissociate from NF-kB, thereby allowing Inhibition of NF-jB activity by vIRF3 of KSHV T Seo et al NF-kB to translocate to the nucleus and bind DNA. We investigated whether vIRF3 inhibits NF-kB activity through the inhibition of IkB phosphorylation. The 293T cells were transfected with vIRF3 expression plasmid or blank vector and then stimulated with TNF-a for 4 min. Cell lysates were prepared and phosphorylation of IkB-a serine 32 was determined by Western blotting using a phospho-IkB-a monoclonal antibody. We found that in unstimulated cells, no phospho-IkB-a was detected following transfection with either blank vector or vIRF3 ( Figure 3 , top panel, lanes 1 and 2). These data indicate that IkB exists in an unphosphorylated form in resting cells, thus preventing NF-kB nuclear localization. The addition of TNF-a significantly increased IkB-a phosphorylation, and this phosphorylation was inhibited by vIRF3 expression (Figure 3 , top panel, lanes 3 and 4). Western blot assays using anti-b-actin monoclonal antibody showed that the total protein in each lane was equal (Figure 3 , bottom panel). These data suggest that vIRF3 downregulates NF-kB activity through the inhibition of IkB phosphorylation.
vIRF3 selectively suppresses IKKb kinase activity
Since vIRF3 inhibited IkB-a phosphorylation (Figure 3 ), we examined whether vIRF3 affected IKK activity. The 293T cells were transfected with expression plasmids encoding either HA-IKKa or FLAG-IKKb, together with vIRF3 expression plasmid. Recombinant IKKs were immunoprecipitated from cell lysates with anti-HA or -FLAG monoclonal antibodies, and kinase activity in these complexes assessed following the addition of the exogenous substrate recombinant IkB-a (GST-IkB-a, 1-62). We found that immunoprecipitates from cells transfected with wild-type IKKa were able to phosphorylate GST-IkB-a, while immunoprecipitates from cells transfected with a kinase dead IKKa mutant did not ( Figure 4a ). These data indicate that GST-IkB-a was exclusively phosphorylated by IKKa in this assay. Similar data were obtained in experiments comparing wild-type and kinase dead IKKb (Figure 4b ). The addition of TNF-a to cells did not increase kinase activity, indicating that activity was at maximum levels following overexpression of IKKa and IKKb, as The 293T cells were cotransfected with Gal4-dependent promoter (pFR-Luc) (1 mg), Gal4-VP16 expression plasmid (0.5 mg), and increasing amounts of pcDNA-vIRF3. In all studies, luciferase activity was measured with a luminometer. The total amount of transfected DNA in each experiment was kept constant by the addition of blank vector (pcDNA3.1). The activity of the reporter alone was set to a value of 1, and luciferase activity changes are presented as 'fold activation'. Luciferase activity was normalized to b-galactosidase activity. Each result is the average from three independent experiments, and the standard deviation is shown Inhibition of NF-jB activity by vIRF3 of KSHV T Seo et al observed by other groups (Geleziunas et al., 1998) . We found that coexpression of vIRF3 significantly reduced IKKb kinase activity, but did not affect IKKa kinase activity ( Figure 4a and b, top panels). Expression levels of IKKs were examined by Western blotting using anti-HA and -FLAG monoclonal antibodies ( Figure 4a and b, bottom panels). We also examined the effect of vIRF3 on IKKb activity in HeLa cells. Unlike in 293T cells, ectopic IKKb activity was dramatically increased . At 24 h after transfection, cells were incubated with or without TNF-a (20 ng/ ml) for 10 min. Cell extracts were immunoprecipitated with anti-HA monoclonal antibody, washed, and subjected to in vitro kinase assay using GST-IkB-a (1-62) as an exogenous substrate. Incubation mixtures were analysed following SDS-PAGE and autoradiography (top panel). Equal amounts of cell extracts were resolved by SDS-PAGE and immunoblotted with anti-HA antibody (bottom panel). (b) The 293T cells were transfected with FLAG-IKKb expression plasmid (pcDNA-FLAG-IKKb) or FLAG-IKKb (KD) expression plasmid (pcDNA-FLAG-IKKb K44A; a kinase dead mutant) in combination with vIRF3 expression plasmid (pcDNAvIRF3). At 24 h after transfection, cells were incubated with or without TNF-a for 10 min. Cell extracts were immunoprecipitated with anti-FLAG monoclonal antibody, washed, and subjected to in vitro kinase assay, SDS-PAGE and autoradiography as described above (top panel). The expression level of FLAG-IKKb and FLAG-IKKb (KD) is shown (bottom panel). (c) HeLa cells were transfected with FLAG-IKKb expression plasmid in combination with vIRF3 expression plasmid. At 24 h after transfection, cells were incubated with or without TNF-a for 10 min. Cell extracts were immunoprecipitated with anti-FLAG monoclonal antibody, washed, and subjected to in vitro kinase assay, SDS-PAGE and autoradiography as described above (top panel). The expression level of FLAG-IKKb is shown (bottom panel) Figure 2 Inhibition of NF-kB activation by vIRF3. The 293T cells were cotransfected with increasing amounts of vIRF3 expression plasmid or IkB-a expression plasmid. At 24 h after transfection, cells were stimulated with TNF-a (20 ng/ml) for 20 min, and nuclear extracts were prepared. Equal amounts of nuclear extracts were used for electrophoretic mobility shift assays using 32 P-labeled NF-kB oligonucleotide probe. The DNA/NF-kB complex (top arrow) and the free probe (bottom arrow) are indicated. Competition assays were performed by preincubation with excess (50-fold) unlabeled wild-type and mutant NF-kB oligonucleotide (lanes 7-10) Figure 3 vIRF3 inhibits TNF-a-induced IkB-a phosphorylation. The 293T cells were transfected with either vIRF3 expression vector (pcDNA3-vIRF3) or blank vector, and incubated with or without TNF-a (20 ng/ml) for 4 min. Equal amounts of total cell extract were resolved by SDS-PAGE and immunoblotted with anti-phospho-IkB-a monoclonal antibody (top panel) or with antib-actin monoclonal antibody (bottom panel)
Inhibition of NF-jB activity by vIRF3 of KSHV T Seo et al by TNF-a in HeLa cells (Figure 4c, top panel) . This TNF-a-stimulated activity was inhibited by vIRF3 expression (Figure 4c, top panel) . The expression level of IKKb was not changed by TNF-a addition or vIRF3 expression (Figure 4c, bottom panel) . Our results indicate that vIRF3 inhibits NF-kB activity through the inhibition of IKKb, but not IKKa, kinase activity.
vIRF3 interferes with nuclear translocation of NF-kB p65 induced by TNF-a Since vIRF3 inhibits IkB phosphorylation, we examined the effect of vIRF3 on NF-kB p65 localization. The 293T cells were transfected with either vIRF3 expression vector or blank vector, and 24 h later were either left untreated or treated with TNF-a for 20 min. The location of endogenous p65 was visualized by immunofluorescence microscopy using an anti-p65 monoclonal antibody. In unstimulated cells, p65 exclusively localized to the cytoplasm, and this was not affected by vIRF3 (Figure 5a , top panels). In TNF-a-stimulated cells, p65 completely translocated to the nucleus and expression of the vIRF3 interfered with this movement (Figure 5a , bottom panels).
To confirm whether the inhibition of a translocation of NF-kB occur in the cells expressing vIRF3, we carried additional immunofluorescence assays. In the cells expressing green fluorescence protein (GFP), p65 translocated to the nucleus after TNF-a stimulation. However, in the cells expressing GFP-vIRF3, p65 was still found in the cytoplasm in spite of TNF-a stimulation. In the cells not expressing GFP-vIRF3, p65 translocated to the nucleus after TNF-a treatment (Figure 5b ). These data indicate that vIRF3 interferes with NF-kB nuclear translocation induced by TNF-a.
Interaction between vIRF3 and IKKb
To determine whether the inhibition of NF-kB is due to physical association with IKKb, we performed in vitro binding assay using 35 S-labeled, in vitro-translated IKKb. GST-vIRF3 was immobilized on glutathione-Sepharose 4B beads, and binding of in vitro-translated IKKb and luciferase to the fusion protein was observed. IKKb specifically interacted with GST-vIRF3, whereas luciferase (used as a negative control) did not interact with GST-vIRF3 (Figure 6a) .
We next determine whether vIRF3 associates with IKKb in vivo. The 293T cells were cotransfected with GST, GST-vIRF3, and FLAG-IKKb expression plasmid. At 48 h after transfection, cells were lysed and incubated with glutathione-Sepharose 4B beads to precipitate GST and GST-vIRF3. The precipitated FLAG-IKKb protein was detected with anti-FLAG antibody. As shown in Figure 6b , FLAG-IKKb protein was co-precipitated with GST-vIRF3, but not with GST. To confirm that FLAG-IKKb, GST, and GSTvIRF3 were expressed properly in transfected cell, we performed a Western blot assay using total cell extracts with anti-FLAG antibody or anti-GST antibody (Figure 6b) . We also performed co-immunoprecipitation assay in KSHV-infected BCBL-1 cells. In contrast to the 293T cells, we failed to detect vIRF3-IKKb interaction in BCBL-1 cells (data not shown). The 293T cells were transfected with either vIRF3 expression vector or blank vector and then incubated with or without TNF-a (20 ng/ml) for 20 min. NF-kB p65 was visualized by immunofluorescence microscopy using an anti-p65 mouse monoclonal antibody and an anti-mouse secondary antibody conjugated with FITC. (b) The 293T cells were transfected with either GFP or GFP-vIRF3 expression vector and then stimulated TNF-a. p65 was visualized by immunofluorescence microscopy using an anti-p65 mouse monoclonal antibody and an anti-mouse secondary antibody conjugated with TRITC
Inhibition of NF-jB activity by vIRF3 of KSHV T Seo et al vIRF3 sensitizes cells to TNF-a-induced apoptosis
Although TNF-a induces cells to undergo apoptosis, it also induces NF-kB activation that prevents TNF-ainduced apoptosis (Van Antwerp et al., 1996 Jiang et al., 1999) , implying the existence of a negative feedback mechanism in TNF-a signaling. Several groups have reported that the suppression of NF-kB results in enhanced TNF-a-induced apoptosis (Beg and Baltimore, 1996; Van Antwerp et al., 1996; Wang et al., 1996; Bakker et al., 1999; Shao et al., 1999) . Since vIRF3 negatively regulates NF-kB, we investigated whether vIRF3 affects TNF-a-induced apoptosis. The 293T cells were transfected with blank vector or vIRF3 expression vector and then left untreated or treated with TNF-a for 24 h. We found that in cells exposed to TNF-a, vIRF3 expression caused morphological changes consistent with cell death (Figure 7a ). These changes were not observed in cells transfected with blank vector alone (Figure 7a ). To confirm that these morphological changes were related to apoptosis, cells were examined using the terminal deoxynucleotidyltransferasemediated dUTP-biotin nick-end labeling (TUNEL) assay. Transiently transfected 293T cells were treated with TNF-a for 24 h, fixed, and subjected to TUNEL analysis. Since the TUNEL reaction used FITC as a labeling reagent, TUNEL-positive cells (apoptotic) show green nuclei using the FITC filter set. We found that the number of TUNEL-positive cells was increased by the combination of vIRF3 expression and TNF-a (Figure 7b ). In addition, in TNF-a-treated cells, we observed a lower number of cells in the population expressing vIRF3 compared to the population not expressing vIRF3 (Figure 7b) . In TNF-a-treated cells, 57.1% of cells expressing vIRF3 were apoptotic, while only 9.0% were apoptotic in cells not expressing vIRF3 (Figure 7c ). Our data demonstrated that vIRF3 enhances TNF-a-induced apoptotic cell death.
Discussion
NF-kB is a transcription factor that plays a role in innate and adaptive immune responses through its ability to regulate production of cytokines, receptors necessary for immune recognition, and proteins participating in antigen presentation (Ouaaz et al., 1999; Silverman and Maniatis, 2001; Karin and Lin, 2002) . Owing to the extensive function of NF-kB in immune response and cell death, viral proteins frequently deregulate NF-kB signal pathways to evade host immune surveillance, promote cell survival, and enhance viral replication (Hiscott et al., 2001) . Many viral proteins induce NF-kB activity, whereas some viral proteins downregulate NF-kB activation.
In this report, we demonstrate that KSHV vIRF3 acts as a negative regulator of NF-kB activity. To respond rapidly to a variety of stimuli, the cytoplasmic NF-kB/ IkB complex is activated by phosphorylation with IKK. Phosphorylation of IkB leads to ubiquitination, resulting in the degradation of IkB, and ultimately leading to nuclear translocation of NF-kB. Since the key step in regulation of NF-kB activation is IkB phosphorylation by IKK, it is rational that we found vIRF3 targets IKK to deregulate NF-kB activity. This strategy is commonly used by other viral proteins that regulate NF-kB. Adenovirus E1A sensitizes cells to g-irradiation-or TNF-a-induced apoptosis by inhibiting NF-kB activity . Cell extracts were precipitated with glutathione-Sepharose 4B. The resulting precipitates were washed and resolved by SDS-PAGE. GST fusion protein and FLAG-IKKb were detected by Western blot with anti-FLAG (top panel) and anti-GST antibodies (bottom panel), respectively. Lanes: 1 and 3, GST with FLAG-IKKb; 2 and 4, GST-vIRF3 with FLAG-IKKb Inhibition of NF-jB activity by vIRF3 of KSHV T Seo et al through the suppression of IKK (Shao et al., 1997 (Shao et al., , 1999 . Human papillomavirus E7 attenuates NF-kB activation by suppressing IKK activity and phosphorylation of IkB (Spitkovsky et al., 2002) . Interestingly, vIRF3 selectively inhibits IKKb kinase activity (Figure 4) , whereas E1A and E7 suppress both IKKa and IKKb kinase activities (Shao et al., 1999; Spitkovsky et al., 2002) , suggesting that viral proteins act differently in targeting IKK for the inhibition of NFkB. IKKa and IKKb show similar substrate specificity, phosphorylating serines 32 and 36 of IkB. However, in vivo analysis using 'knockout' mice showed that IKKb is a more potent regulator of NF-kB than IKKa (Chu et al., 1999; Hu et al., 1999 Hu et al., , 2001 Li et al., 1999a, b) . This apparently greater importance of IKKb in NF-kB activation possibly explains why vIRF3 targets IKKb rather than IKKa.
To examine the role of vIRF3 on IKKb inhibition, we checked direct binding between vIRF3 and IKKb using with co-immunoprecipitation assay. In 293T cells, overexpressed vIRF3 was co-immunoprecipitated with overexpressed IKKb (Figure 6b ). However, in KSHVinfected BCBL-1 cells, we were unable to demonstrate the direct interaction between endogenous vIRF3 and IKKb (data not shown). These results indicated that there are some differences between overexpression system and authentic system. More studies are required for elucidating the molecular interactions between vIRF3 and IKKb.
In general, NF-kB acts as an antiapoptotic transcriptional regulator. TNF-a induces recruitment of the Fasassociated death protein to the cytoplasmic domain of its type I receptor, resulting in the activation of caspase-8. However, TNF-a also induces NF-kB activation that leads to the inhibition of TNF-a-induced apoptosis (Karin and Lin, 2002) . Therefore, suppression of NF-kB results in the enhancement of TNF-a-induced apoptosis (Beg and Baltimore, 1996; Van Antwerp et al., 1996; Wang et al., 1996; Bakker et al., 1999; Shao et al., 1999) . Our data indicate that vIRF3 sensitizes cells to TNF-a through inhibiting NF-kB (Figure 6 ), and that vIRF3 can promote apoptosis under certain conditions. Although Rivas et al. (2001) reported that vIRF3/ LANA2 inhibited p53-induced apoptosis, their results are not necessarily contradictory to ours, since NF-kB is proapoptotic in p53-induced apoptosis, but is antiapoptotic in many systems, including TNF-a-induced apoptosis (Ryan et al., 2000) . Hence, the dramatic inhibition of p53-induced apoptosis by vIRF3/LANA2 may be the result of additive effects of NF-kB inhibition in combination with p53-vIRF3/LANA2 interaction.
In PEL cells latently infected with KSHV, the level of NF-kB is high, and the inhibition of NF-kB leads to lytic protein synthesis consistent with virus reactivation, suggesting that NF-kB is a potential in vivo regulator of the balance between lytic replication and latency (Brown et al., 2003) . The constitutive activation of NF-kB in PEL cells is mostly due to viral FLICE inhibitory protein (vFLIP) (Liu et al., 2002) . As NF-kB is activated in PEL cells, vFLIP may be more dominant factor than vIRF3 for NF-kB regulation. One possible mechanism of the regulation of viral latency is that inhibition of IKKb by vIRF3 results in NF-kB inhibition, then followed by viral lytic change.
In conclusion, our data suggest that vIRF3 inhibits NF-kB activation and sensitizes TNF-a-induced apoptosis. This inhibition of NF-kB by vIRF3 is related to the suppression of IKKb activity followed by the inhibition of nuclear translocation of NF-kB. Owing to the pivotal role of NF-kB in immune system and cell death regulation, many viral proteins regulate NF-kB activity. By inhibiting NF-kB activity, vIRF3 potentially modulates the host immune system and deregulates apoptosis.
Materials and methods
Plasmids
The vIRF3/LANA2 expression plasmid (pcDNA-vIRF3/ LANA2) was a kind gift from Dr Yuan Chang. The following plasmids were gifts from Dr Warner C Greene: pcDNA-HAIKKa (WT), pcDNA-HA-IKKa (K44M), pcDNA-FLAGIKKb (WT), pcDNA-FLAG-IKKb (K44A), pGST-IkBa (1-62), and pCMV4-HA-IkBa (SS32/36AA). The pEBG-vIRF3 construct expressing GST fused to vIRF3 was generated by subcloning into the BamHI/NotI sites of pEBG. pGFP-vIRF3 was constructed by pEGFP-C1 (Clontech, Palo Alto, CA, USA). The pELAM-CAT reporter plasmid (Whelan et al., 1991) was a gift from Dr John F DeLamarter. To generate the pELAM-Luc reporter, the region of À385 to þ 80 was amplified by PCR using pELAM-CAT as a template and then subcloned into pGL2-basic (Promega, Madison, WI, USA) at MluI/BglII sites. The HIV-LTR-Luc reporter plasmid was generously provided by Dr M Benkirane. The synthetic NFkB-dependent reporter plasmid (p3 Â NF-kB-Luc) was a kind gift from Dr Yusang Gwack.
Cell culture, transfection, and reporter assays
The 293T and HeLa cells were grown in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum. Transfections were performed by the calcium phosphate method (Graham and van der Eb, 1973) in 293T cells. The transfected plasmids were prepared using the Qiagen midiprep procedure (Qiagen, Hilden, Germany), and the total amount of plasmid was adjusted with a blank plasmid lacking the cDNA to be expressed. At 24 h after transfection, cells were treated with TNF-a (Sigma, St Louis, MO, USA). Equal amounts of cell extracts were employed for the detection of luciferase activity. Each assay was normalized using bgalactosidase activity. HeLa cells were transfected with Superfect reagent (Qiagen) following the manufacturer's instructions.
Nuclear extracts preparation
Nuclear extracts were prepared from control and TNF-astimulated 293T cells. Briefly, cells from 100-mm dishes were washed with cold phosphate-buffered saline (PBS) and scraped into test tubes. Cells were again washed and then suspended in 300 ml cold HB cell lysis buffer (10 mM HEPES, pH 7.9; 1.5 mM MgCl 2 ; 1.5 mM dithiothreitol (DTT); 0.1 mM PMSF; 1 mg/ml leupeptin). The suspended cells were incubated on ice for 15 min and then lysed using a homogenizer (30 strokes). After centrifugation, pellets were washed with cold HB cell lysis buffer and resuspended in 100 ml cold buffer C (30 mM HEPES, pH 7.9; 1.5 mM MgCl 2 ; 0.3 mM EDTA; 450 mM NaCl; 10% glycerol; 0.1% Nonidet P-40; 1 mM DTT; 0.1 mM PMSF; 1 mg/ml leupeptin). Nuclear membranes were disrupted with 15 homogenizer strokes. After centrifugation, the supernatant was collected, added to an equal volume of buffer D (30 mM HEPES, pH 7.9; 1.5 mM MgCl 2 ; 0.3 mM EDTA; 10% glycerol; 1 mM DTT; 0.1 mM PMSF; 1 mg/ml leupeptin), and frozen at À701C until ready for use.
Electrophoretic mobility shift assay
The wild-type double-strand NF-kB oligonucleotide sequence used as a probe was 5 0 -GATCTCAGAGGGGACTTTCCGA GAGA-3 0 and its complementary strand. The mutant doublestrand NF-kB oligonucleotide sequence was 5 0 -GATCTCA GACTCTTCTTTCCGAGAGA-3 0 and its complementary strand. Each oligonucleotide was end-labeled with [g-32 P]ATP using T4 kinase (Promega). Binding reactions were performed at 41C for 15 min in a total volume of 20 ml reaction mixture containing 30 mM HEPES (pH 7.9), 1.5 mM MgCl 2 , 0.3 mM EDTA, 100 mM NaCl, 10% glycerol, 1 mM DTT, 0.1 mM PMSF, 1 mg/ml leupeptin, the labeled probe (30 000 c.p.m.), and nuclear extract. For competitive binding reactions, a 50-fold molar excess of unlabeled wild-type NF-kB or mutant NF-kB double-strand oligonucleotide was preincubated in the reaction mixture at 41C for 5 min before adding labeled probe. Analysis of binding complexes was performed by electrophoresis in 5% native polyacrylamide gels (PAGE) with 0.5 Â Trisborate electrophoresis buffer and bands visualized using autoradiography.
Immune complex kinase assay
The 293T cells and HeLa cells were cotransfected with expression plasmids encoding for HA-or FLAG-tagged IKK and vIRF3. At 24 h after transfection, cells were either untreated or treated with TNF-a (20 ng/ml) for 10 min, then lysed with cell lysis buffer (50 mM HEPES, pH 7.4; 250 mM NaCl; 1 mM EDTA; 1% Nonidet P-40; protease inhibitor cocktail (Roche Molecular Biochemicals, Mannheim, Germany)). Cell extracts were incubated with anti-HA or anti-FLAG antibody for 1 h and then incubated with protein GSepharose beads (Amersham Pharmacia Biotech, Uppsala, Sweden). Immunoprecipitates were washed four times with cell lysis buffer and then once with kinase buffer (10 mM HEPES, pH 7.4; 1 mM MnCl 2 ; 5 mM MgCl 2 ; 12.5 mM b-glycerophosphate; 2 mM NaF; 50 mM sodium orthovanadate; 50 mM DTT; 10 mM ATP). After suspension in 30 ml kinase buffer, immunoprecipitates were incubated with 5 mCi [g-32 P]ATP and 1 mg GST-IkB-a (1-62) for 30 min at 301C. The kinase reaction was terminated by the addition of sodium dodecyl sulfate (SDS) sample buffer. The samples were subjected to SDS-PAGE and bands visualized using autoradiography.
Immunofluorescence
The 293T cells were fixed with 3.7% formaldehyde in PBS for 30 min, permeabilized on ice with PBS containing 0.2% Triton X-100, blocked with 1% bovine serum albumin, incubated with primary antibody in PBS containing Triton X-100 and 1% bovine serum albumin for 1 h, and washed three times with PBS containing 0.2% Triton X-100. Cells were incubated with secondary antibody in PBS containing 0.2% Triton X-100 and 1% bovine serum albumin and washed three times with PBS containing 0.2% Triton X-100. Analyses were performed with a Zeiss (Oberkochen, Germany) confocal microscope with FITC and TRITC filter sets.
Inhibition of NF-jB activity by vIRF3 of KSHV T Seo et al
In vitro binding assay
Wild-type GST and GST-IKKb were prepared by the expression of 293T cell containing GST or GST-IKKb expression vector. Following lysis by sonication, GST fusion proteins were bound to glutathione-Sepharose 4B beads, washed with PBS and eluted with buffer containing 25 mM glutathione.
35 S-labeled proteins were synthesized in vitro using the TNT-coupled transcription-translation system (Promega, Madison, WI, USA), as described by the manufacturer. Purified or Sepharose 4B-bound GST-fusion protein was incubated with 35 S-labeled proteins in 500 ml binding buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 5 mM EDTA, pH 8.0; 2.5 mM DTT; 0.7 mg/ml bovine serum albumin; 0.1% Nonidet P-40) at 41C for 3 h. The precipitated protein complexes were washed five times with binding buffer. Bound proteins were analysed by SDS-PAGE and autoradiography.
In vivo binding assay
The 293T cells were transiently cotransfected either with GST or GST-vIRF3 in combination with HA-IKKa or FLAGIKKb. After 48 h of transfection, cells were lysed with EBC buffer (50 mM Tris-HCl, pH 7.5; 120 mM NaCl; 0.5% Nonidet P-40; 50 mM NaF; 200 mM sodium orthovanadate; 1 mM PMSF) and incubated with glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech) at 41C for 2 h with rocking. Bound protein complexes were washed three times with EBC buffer and heated to 951C for 5 min in SDS sample buffer. Western blots were performed using anti-HA, anti-FLAG and anti-GST antibodies. BCBL-1 cells were lysed with EBC buffer and immunoprecipitated with anti-IKKb or anti-FLAG mouse monoclonal antibody, as described above. Samples were immunoblotted with anti-vIRF3 monoclonal antibody.
Apoptosis assay
The 293T cells grown on coverslips in 35-mm diameter dishes were transfected with Superfect reagent as recommended by the manufacturer (Qiagen). At 12 h after transfection, cells were treated with TNF-a (20 ng/ml) for 24 h and fixed with 4% paraformaldehyde in PBS. TUNEL reactions were performed with an in situ cell detection kit as recommended by the manufacturer (Roche Molecular Biochemicals). Analyses were performed using a Zeiss confocal microscope with FITC filter sets. The proportion of cells undergoing apoptosis was determined by counting both total and green apoptotic cells in multiple fields.
